RPRXRoyalty Pharma plc
Pharmaceutical Preparations
- Revenue
- $2.4B
- 5.1% YoY
- Operating margin
- 65.6%
- 15% YoY
- EBITDA
- $1.6B
- 21% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 5.2×
- $8.1B net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear323% of net incomeCash flow under 80% of net income
- Dilutive SBCFired12% of revenueOver 10% of revenue
- Payouts exceed cash flowClear49% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear5% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B | 5.1% |
| Operating income | $1.4B | $307M | $1.5B | $1.3B | $1.6B | 21% |
| Net income | $620M | $43M | $1.1B | $859M | $771M | 10% |
| Operating cash flow | $2.0B | $2.1B | $3.0B | $2.8B | $2.5B | 10% |
| Stock-based comp | $2M | $2M | $2M | $2M | $290M | 12267% |
| Buybacks | $0 | $0 | $305M | $230M | $1.2B | 434% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $6M · 4
- Net
- −$6M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $938K | $83M | 85 | 206 |
| FY2024 | — | $191M | 57 | 170 |
| FY2023 | — | $27M | 61 | 152 |
| FY2022 | — | $46M | 82 | 141 |
| FY2021 | — | $57M | 81 | 128 |